GENOMEZ The PCR Screening Test RE-WIRED

The COVID-19 Pandemic exposed an imbalance between Molecular Diagnostic infrastructure capacity & Demand , Genomez a Project started at MIT COVID-19 Beat The Pandemic Hackathon Named then COVID-19 Trace Coin evolved to Ggenomez, Empowering PCR testing Capacity by integrating Data science using AI, ML Technologies to multiply capacity of existing molecular laboratory infrastructure between 5 to 10 folds for high test positive rates

Pooling Test strategies did not achieve its potential due to false positive results as one positive masks true negative samples with positive interpretation which mandates second run of pooling or individual testing, Known as Reopening of Positive Pool Groups this is a challenge to MoDx setup due to limited resources of skilled personnel and the 2nd challenge to recall individuals for retest. 

Lab automation set the stage for the solution developed by Genomez  transforming Pooling Test into one run with application from infectious diseases to cancer detection.

as COVID-19 Testing Will continue to be required even as vaccination is rolled out to protect those who are vulnerable a testing solution will be required to reduce cost of the test this achieved a plateau as prices dropped significantly from initially 20USD on average at the beginning of the pandemic to 5USD or less per test as a transfer price from manufacturers.

Even with existing pricing at 5 USD with chain of Distribution and Service cost on average the test in Europe is 18 Euros for example in Germany and 100 USD in the United States and 50 USD in Developing Nations.

our objective to decimate testing price via increasing capacity 5 folds in high test positive rates as much 5% and 10 folds if test positive rates falls below 1% test positive rate.

The Solution Developed by Genomez has other use cases e.g. Sepsis Diagnosis a World Health Organization Priority Status where MoDx test cost from manufacturer between 65 to as much 130 USD decimating this will make MoDx for Sepsis very competitive against blood culture from cost basis and reduces testing time to just under three hours saving lives by 80% of 50 Million individuals affected annually.

Genomez Solution provides PCR Test Pooling Strategy transforming PCR Pooling Test from Multistep PCR step process to Identify True Positive into one single run with zero false positive and zero false negative in one single run.

Genomez Proposed solution uses 3 elements of AI,ML algorithms a dynamically design pooling strategy with Zero False Positive & No false Negative, Maintaining  Sensitivity & Specificity of the Molecular Diagnostic Tests to be used.

Where conventional Pooling Test which need to re-opened if one true positive mask other true negative samples via re-pooling, individual re-testing shall be avoided using our solution data-sets of initial runs taking in consideration high test positive rates to reach maximum pooling testing capacity.

Building am innovative solution maximizing lab capacity requires most advanced technologies to capitalize on networking effect, using DLT Blockchain on SaaS Model with plug and play functionality transform any lab from 1x to 30x in seconds with a click of a button via internet connectivity.

Genomez business model makes the solution exponentially scalable and versatile based on its modular nature without dependence on intermediaries for fulfilment nor for payment collection each run can reduce cost by 80-90% against small that has ROI in Saving exceeding 25600%.

The Use of AI & ML with Data Sets using Data Science was developed to address different use cases from COVID-19 , Sepsis diagnosis partnering with a leader in Sepsis MoDx Diagnotic Test Manufacturer Cube Dx GmbH and our MoDx Technology partner in Genomez.this can be combined with AI ML & Deep learning that can identify risk of suspecting sepsis 

Such a combination will reduce the use of broad spectrum empiric antibiotic use to just one dose followed by targeted antibiotics those are three main components of actions required thus reducing the risk of an emerging Anti-Microbial Resistance AMR (Min34:38) WHO DG Address on WHO global Action Plan for AMR(Min4:00) Action Plan(14:10)

The increase MoDx infrastructure capacity in Many Countries who lacked it before the pandemic has set the global stage if such testing capacity especially when Genomez solution increases 10 to 30 folds in combating Tuberculosis. The Molecular Diagnostic MoDx in TB reduces time for Diagnosis from Weeks to hours and will curb the Spread of TB XDR & MDR a major challenge emerging of AMR Anti-Microbial Resistance in Tuberculosis Management, Given that genotypic tests can rapidly detect the prominent mechanisms of resistance, such as the rpoB mutation for rifampicin resistance, we are facing new challenges with the observation of false-resistance (mutations not conferring resistance) and false-susceptibility (mutations different from the common mechanism) results.

in addition Genomez solution could be implemented on Liquid Biopsy of Circulating Nucleic Acid Fragments (cnf) form tumors and tested by PCR testing for Cancer Early detection where the test positive rate are extremely low thus the potential of increased capacity could reach thirty folds thus reducing cost for National screening program for up to 50 possible tumors using The Galleri Test developed by a company called Grail by 97%.

Molecular Diagnostic Technologies is changing the golden standards of disease surveillance, Early warning for Predictive systems providing the Most accurate data in pathogen identification which will slow hault future disease outbreaks.

But for Many countries including developed countries capacity was a problem at the beginning of the pandemic, Now this is still a problem for underdeveloped nations.

Genomez Focused on Molecular Diagnostic Gold Standard The PCR Test and empowering it with AI & ML as well Deep Learning to increase capacity by plug and play business model multiplying laboratories capacities between 5 to 10 folds by click of a button  

Our Team Worked on the following

1- Ideation process was made on MIT COVID19 Challenge

2- Developing AI & ML Algorithms and hosted it on AWS thus the Algorithms are TLR level 6-7 By Dr Alexey Gusarov & with Supervision of Professor Alexey S. the Advisor of our company

3- we carried out clinical validation for the solution involving two positive out of 42 samples in India via our co founder Dr Carlos Justin where testing Sensitivity and specificity was made

4- We Have tested the SARS-CoV-2 RT PCR test Developed by our Partner Cube Dx and we received confirmation of those results at X Prize under Viral Testing inc. A semifinalist on X-Prize COVID-19 Testing Challenge , and the test is CE IVD and Approved for use in EU

5- Received First runner up MITEF Arab Startup Competition 2021 Idea Track and 3rd Place on MITEF Saudi Arabia 2020-2021

Tapestry Pooling Test strategy concept has been present for some time its the adoption AI, ML Algorithms on pooling strategy innovative , Genomez solution  one run pooling test with zero false positive and no false negative integrated to web 3.0 in plug and play model using DLT Blockchain smart contract makes it innovative solution eleminating the need for distribution channels and increasing lab capacity by plug and play and click to increase lab capacity 5 to 10 folds with cost saving ROI up to 25600%.

many used bloom filter in pooling strategy but this did not eliminate a second run to reopen pooled samples it increased efficiency of the  pooling test

currently we are not commercial 

in one year we will conduct clinical trials 

In three to five years potential MoDx penetration of 30% of all Screening Test

In Tuberculosis 3 Million Cases 

For Sepsis 15 Million Cases 

For COVID-19 Test ONLY 5% Could reach 50 million test annually  

first achievement the algorithm and patent applied for it

second achievement clinical validation of the protocol up and running on actual clinical samples 

third goal to be completed  assay designs for different tests in our objective plan    

fourth goal integration process with MoDx  Equipment Manufacturers and Reagent Manufacturers 

Dr Fawaz Linjawi CEO and Founder fulltime

Dr Alexey Gusarov Cofounder PhD Data Since  AI ML Developer  CTO , Part Time

Shadh Linjawi Co-Founder Molecular Biology Student University of Washington, Part Time Internship during summer

Dr Carlos Justin Co-Founder  Assistant professor Biotechnology Part time

Dr Dina Lary  Co-Founder PhD Molecular Microbiology Part time

Mrs Hebah Jamjoom  MBA Project Manager & CFO

Advisors

Dr Alexey S PhD Data Since AI & ML advisor

Mr Christoph Reschreiter  CEO Cube Dx

the Team includes a my self a physician Fawaz , Molecular Biotechnologist Dr Justin and Molecular Microbiologist Dr Lary together with an AI & Ml Expertise and data since Dr Gusarov and advisory board professor Alexey Data Since and CEO of Cube Dx    

our team is truly global and diverse 

Fawaz Linjawi resident in Jeddah KSA  

Shahd Linjawi Resident in Seattle WA USA

Dr Alexey Gusarov Resident in Moscow Russia

Dr Carlos Justin Resident in Chennai India 

Dr Dina Lary resident in Jeddah KSA

Mrs Hebah Jamjoom Resisdent in Jeddah KSA

Advisory

Dr Alexey S Resident in San Diego CA USA

Mr CHristoph Reschreiter Resident Linz Austria 

MIT SOLVE is A prestigious Award if we become a Solver 

this will accelerate or traction to serve humanity by eliminating barriers to Move to the United States and obtain BARDA Grant and if lucky join MIT Innovation Initiative program   

any Startup would require mentoring to succeed all support that cana be provided will help this social impact project 

MIT Innovation Initiative 

BARDA

CDC

University Of Washington Molecular Biology & AI & ML division of Computer science

Quest Diagnostic 

our solution affect health pf all global citizens including Citizens of the USA

Refugee camps are affected more than any other from infectious diseases and with very limited resources our solution can bring cost of diagnosis 90% lower

the Diagnosis of Group B Streptococci in peripartum check up to have a safe delivery for mothers and their babies 

our solution is based on AI & ML to reduce Morbidity & Mortality in Humanity